Intravitreal Ranibizumab for Patients with Neovascular Age-Related Macular Degeneration with Good Baseline Visual Acuity

Publisher： Karger

E-ISSN： 1423-0267|233|1|27-34

ISSN： 0030-3755

Source： Ophthalmologica, Vol.233, Iss.1, 2014-11, pp. : 27-34

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Three-Year Visual Outcome and Injection Frequency of Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 230, Iss. 1, 2013-04 ,pp. : 27-33

Karger

Access to resources Recommend Favorite

Visual acuity and its decrease in classic neovascular age-related macular degeneration

By Behrendt Carolyn  

Ophthalmic Epidemiology, Vol. 11, Iss. 5, 2004-12 ,pp. : 359-367

Informa Healthcare

Access to resources Recommend Favorite

Bimonthly Ranibizumab for Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 231, Iss. 2, 2013-12 ,pp. : 80-85

Karger

Access to resources Recommend Favorite

Comparative Study of Intravitreal Bevacizumab (Avastin) versus Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 223, Iss. 6, 2009-07 ,pp. : 370-375

Karger

Access to resources Recommend Favorite

Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial

By  

Ophthalmologica, Vol. 234, Iss. 1, 2015-06 ,pp. : 40-54

Karger

Access to resources Recommend Favorite